Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 248353.33%.

  • Lyell Immunopharma's EBIT Margin fell 998092200.0% to 248353.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 836358.54%, marking a year-over-year decrease of 4917299700.0%. This contributed to the annual value of 588122.95% for FY2024, which is 3981168000.0% down from last year.
  • As of Q3 2025, Lyell Immunopharma's EBIT Margin stood at 248353.33%, which was down 998092200.0% from 589250.0% recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's EBIT Margin ranged from a high of 30.55% in Q4 2022 and a low of 2214566.67% during Q3 2022
  • Its 5-year average for EBIT Margin is 481716.77%, with a median of 236156.0% in 2023.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by 2000000000bps in 2022, then skyrocketed by 2000000000bps in 2023.
  • Quarter analysis of 5 years shows Lyell Immunopharma's EBIT Margin stood at 1684.55% in 2021, then skyrocketed by 98bps to 30.55% in 2022, then tumbled by -1498065bps to 457753.85% in 2023, then tumbled by -299bps to 1828609.09% in 2024, then soared by 86bps to 248353.33% in 2025.
  • Its EBIT Margin stands at 248353.33% for Q3 2025, versus 589250.0% for Q2 2025 and 819528.57% for Q1 2025.